Comparative Pharmacology
Head-to-head clinical analysis: NEPHROSCAN versus SETHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHROSCAN versus SETHOTOPE.
NEPHROSCAN vs SETHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
SETHOTOPE is a radiolabeled monoclonal antibody that binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells, delivering beta radiation (177Lu) to cause DNA damage and cell death.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
1.0 mg IV every 12 hours for 7 days.
None Documented
None Documented
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 12 hours (range 10-14 h); clinically, dosing interval is 12-24 h to maintain therapeutic levels
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Renal: 70% as unchanged drug; fecal: 25% as metabolites; biliary: 5%
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical